Histone Deacetylase Inhibitor
Abexinostat for Follicular Lymphoma
Recruiting1 awardPhase 2
Park Ridge, Illinois
This trial is testing a new drug for people with a certain type of cancer who have had three or more types of treatment already. The drug is given two days in a row, then the patient rests for a week, and the cycle repeats.
Cancer Vaccine
Neoantigen Vaccine + Pembrolizumab for Follicular Lymphoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying a new type of FL vaccine which may be a treatment for follicular lymphoma. The agents used in this study are Rituximab, a personalized NeoAntigen vaccine, Poly-ICLC, and Pembrolizumab.
B-cell Lymphoma-2 (BCL-2) Inhibitor
Ibrutinib + Venetoclax for Follicular Lymphoma
Recruiting1 awardPhase 1 & 2
Washington, District of Columbia
This trial is testing a new drug for patients with relapsed or refractory grade 1-3a follicular lymphoma. The trial will enroll patients in a standard 3+3 design to determine the maximum tolerated dose (MTD) of the new drug. Once the MTD is determined, there will be a 17-patient phase II study.
Anti-tumor antibiotic
Rituximab + Pembrolizumab +/- Lenalidomide for Lymphoma
Recruiting3 awardsPhase 2
Houston, Texas
This trial will study how well rituximab and pembrolizumab with or without lenalidomide works in treating patients with follicular lymphoma or diffuse large B-cell lymphoma that has returned after a period of improvement.
Popular Filters
Trials for FL Patients
BCL-2 Inhibitor
PF-06821497 for Small Cell Lung Cancer
Recruiting1 awardPhase 1
Tucson, Arizona
This trial is testing a new drug called PF-06821497 to see if it can help adults with certain hard-to-treat cancers. The drug is taken by mouth and is being studied alone or with other treatments to check its safety and effectiveness in stopping cancer growth.
Trials for Non-Hodgkin's Lymphoma Patients
Monoclonal Antibodies
Immunotherapy for Lymphoma
Recruiting1 awardPhase 2
Seattle, Washington
This trial is testing a combination of two immunotherapy drugs to treat patients with either follicular lymphoma or diffuse large B cell lymphoma that has returned or doesn't respond to treatment. The immunotherapy drugs are pembrolizumab and either rituximab or obinutuzumab. Rituximab and obinutuzumab are monoclonal antibodies that bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. The drugs may help kill more cancer cells.
Monoclonal Antibodies
Obinutuzumab-Based Therapy for Follicular Lymphoma
Recruiting1 awardPhase 2
Anchorage, Alaska
This trial is testing obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy to treat patients with grade I-IIIa follicular lymphoma that has come back or does not respond to treatment.
Trials for Metastatic Patients
BCL-2 Inhibitor
PF-06821497 for Small Cell Lung Cancer
Recruiting1 awardPhase 1
Tucson, Arizona
This trial is testing a new drug called PF-06821497 to see if it can help adults with certain hard-to-treat cancers. The drug is taken by mouth and is being studied alone or with other treatments to check its safety and effectiveness in stopping cancer growth.
Immunomodulatory Agent
Rituximab + Lenalidomide + Ibrutinib for Follicular Lymphoma
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is testing the side effects and best dose of two drugs, lenalidomide and ibrutinib, when given with a third drug, rituximab, to treat patients with follicular lymphoma that has not been treated before.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Follicular Lymphoma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial will compare ibrutinib + rituximab vs rituximab alone in people with untreated follicular lymphoma. The goal is to see if ibrutinib helps people live longer without the cancer progressing.
Trials for CD20 Positive Patients
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Follicular Lymphoma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial will compare ibrutinib + rituximab vs rituximab alone in people with untreated follicular lymphoma. The goal is to see if ibrutinib helps people live longer without the cancer progressing.
Anti-metabolites
Epcoritamab + R2 for Follicular Lymphoma
Recruiting3 awardsPhase 3
Berkeley, California
This trial is testing a new drug combination to treat adults with a type of cancer called follicular lymphoma that has returned or resisted other treatments. The new drug, epcoritamab, is used with lenalidomide and rituximab to help the immune system fight the cancer. The study will check how safe and effective this treatment is.
Monoclonal Antibodies
Epcoritamab + Rituximab + Lenalidomide for Lymphoma
Recruiting2 awardsPhase 3
Des Moines, Iowa
This trial tests a new drug combination for adults with untreated follicular lymphoma, a type of blood cancer. The new treatment includes epcoritamab, lenalidomide, and rituximab, which work together to help the immune system attack cancer cells. The study will check how safe and effective this combination is. Lenalidomide combined with rituximab has shown high efficacy in both relapsed/refractory and untreated follicular lymphoma.
Phase 3 Trials
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Follicular Lymphoma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial will compare ibrutinib + rituximab vs rituximab alone in people with untreated follicular lymphoma. The goal is to see if ibrutinib helps people live longer without the cancer progressing.
Anti-tumor antibiotic
Tafasitamab + Lenalidomide + Rituximab for Follicular & Marginal Zone Lymphoma
Recruiting1 awardPhase 3
San Diego, California
This trial is testing if adding two drugs, tafasitamab and lenalidomide, to an existing treatment (rituximab) is more effective than just adding one drug (lenalidomide) for patients with certain types of lymphoma that have returned or not responded to treatment. The drugs aim to better target and destroy cancer cells while boosting the body's immune response against the cancer. Lenalidomide has shown activity in various lymphoma subtypes, including diffuse large B-cell lymphoma, and is often combined with rituximab for enhanced efficacy.
Immunomodulatory agent
Tazemetostat + Lenalidomide + Rituximab for Follicular Lymphoma
Recruiting1 awardPhase 3
Mobile, Alabama
This trial is testing a new combination drug to treat people with a certain type of lymphoma who have not responded to other treatments. The trial will use biomarkers to select patients most likely to benefit from the new drug.
Anti-metabolites
Epcoritamab + R2 for Follicular Lymphoma
Recruiting3 awardsPhase 3
Berkeley, California
This trial is testing a new drug combination to treat adults with a type of cancer called follicular lymphoma that has returned or resisted other treatments. The new drug, epcoritamab, is used with lenalidomide and rituximab to help the immune system fight the cancer. The study will check how safe and effective this treatment is.
CAR T-cell Therapy
Axicabtagene Ciloleucel for Follicular Lymphoma
Recruiting2 awardsPhase 3
Nashville, Tennessee
This trial is comparing a new treatment to the current standard of care for people with a certain type of lymphoma that has come back or doesn't respond to treatment. They will be looking at how well the new treatment works compared to the current standard by measuring how long people live without the disease getting worse.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.